MentalHealthDaily

Cognitive Function Does Not Predict Response to tDCS for Depression (2023 Trial)

Transcranial Direct Current Stimulation (tDCS) has been explored as a potential treatment for major depressive disorder (MDD), particularly for patients who have not responded to traditional treatments like selective serotonin reuptake inhibitors (SSRIs). This non-invasive technique involves applying a weak electrical current to the prefrontal cortex of the brain, aiming to modulate neurocognitive functions. However, …

Electroconvulsive Therapy (ECT) & Long-Term Cognitive Effects in Major Depression (2023 Review)

by GLOOM

Electroconvulsive therapy (ECT) has long been a controversial yet potent treatment for major depressive disorder (MDD), particularly in cases resistant to conventional therapies. Despite its effectiveness, the long-term cognitive effects of ECT have been a subject of intense debate. A recent meta-analysis offers new insights into these cognitive changes, shedding light on the nuances of …

Aesthetic Chills to Treat Depression? Psychogenic Shivers, Frisson, Goosebumps (2024 Study)

by GLOOM

Depression, a prevalent mental health issue, often resists traditional treatments, making innovative approaches necessary. Recent research suggests that ‘aesthetic chills’—a peak emotional response accompanied by physical sensations like goosebumps—might offer significant benefits in treating depression. Highlights: Prevalence of Depression: Over 300 million people worldwide suffer from depression, making it a critical global health concern. Limitations …

Semaglutide & Empagliflozin May Treat Obesity-Related Cognitive Impairment (Mouse Study)

by GLOOM

Obesity now affects over 650 million adults globally and is a major risk factor for various chronic diseases including cognitive decline and impairment. Recent evidence shows a link between obesity, reduced brain volume and neuronal loss, increased dementia risk, and impaired learning, memory and cognition. Preliminary evidence suggests that weight loss drugs like semaglutide may …

Long COVID Brain Fog & Cognitive Deficits Linked to Specific Biomarkers

by GLOOM

A large prospective study has uncovered two blood biomarker profiles measured during acute COVID-19 that are associated with cognitive deficits months later. Higher fibrinogen and lower C-reactive protein predict both objective and subjective cognitive impairment. Higher D-dimer and lower C-reactive protein predict subjective deficits and occupational impact. Key Facts: In 1,837 COVID-19 patients, two acute …

Qsymia Side Effects & Adverse Reactions (List)

by GLOOM

Qsymia is a weight loss drug engineered by the California-based pharmaceutical company Vivus Inc. It was initially approved by the FDA in 2012 for weight reduction among adults with BMIs (body mass indexes) exceeding 30 kg/m² as an adjunct to interventions such as caloric restriction, dietary modification, and regular exercise. Qsymia is also approved for …